CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Sweden's Medivir Q3 revenue falls, EBITDA loss widens

By Reuters News


Overview

  • Sweden drug developer's Q3 revenue fell yr/yr, EBITDA loss widened

  • Company completed SEK 140 mln share issue, securing funding until at least 2030

  • Company advanced clinical programs and gained US patent protection for fostrox combination


Outlook

  • Company did not provide specific financial guidance or outlook for the current or future periods in its press release


Result Drivers

  • CLINICAL TRIAL PROGRESS - Co said FLEX-HCC phase 2 study for fostrox in advanced liver cancer is recruiting patients as planned

  • PIPELINE DEVELOPMENT - Preparations for proof-of-concept studies with MIV-711 in rare bone diseases are advancing, with partner selection underway for Perthes disease

  • OUT-LICENSED PROJECTS - Partner-led studies of out-licensed assets, including MIV-701 and remetinostat, are advancing and may generate future milestone or royalty payments


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

SEK 700,000

Q3 Adjusted Free Cash Flow

-SEK 14.70 mln

Q3 EBITDA

-SEK 15.90 mln


Analyst Coverage

  • Wall Street's median 12-month price target for Medivir AB is SEK4.35, about 228.1% above its November 4 closing price of SEK1.33


Reuters Recommended Reads

  • Nov 5 - Rare disease drug developer Egetis Q3 revenue rises on EMCITATE sales

  • Nov 5 - Sweden's Camurus Q3 revenue beats estimates on Buvidal, Brixadi growth

  • Nov 3 - Mirum Pharmaceuticals Q3 net product sales surge, outlook raised


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.